Patents Assigned to FIVE PRIME PHARMACEUTICALS, INC.
  • USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2
    Publication number: 20140227263
    Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
    Type: Application
    Filed: November 14, 2013
    Publication date: August 14, 2014
    Applicant: FIVE PRIME PHARMACEUTICALS, INC.
    Inventors: Thomas Harding, W. Michael Kavanaugh